Literature DB >> 17088482

Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.

T S Skinner-Adams1, K T Andrews, L Melville, J McCarthy, D L Gardiner.   

Abstract

The antimalarial activity of several antiretroviral protease inhibitor combinations was investigated. Data demonstrate that ritonavir and saquinavir behave synergistically with chloroquine and mefloquine. These data, and interactions with pepstatin-A, E-64, and bestatin, suggest that human immunodeficiency virus protease inhibitors do not target digestive-vacuole plasmepsins.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17088482      PMCID： PMC1797772          DOI： 10.1128/AAC.00840-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy.

Authors:  A Levi Omara-Opyene; Pedro A Moura; Carlos R Sulsona; J Alfredo Bonilla; Charles A Yowell; Hisashi Fujioka; David A Fidock; John B Dame
Journal:  J Biol Chem       Date:  2004-10-18       Impact factor: 5.157

Review 2.  Therapeutic drugs for targeting chloroquine resistance in malaria.

Authors:  Vijay Sharma
Journal:  Mini Rev Med Chem       Date:  2005-04       Impact factor: 3.862

3.  Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.

Authors:  Sunil Parikh; Jun Liu; Puran Sijwali; Jiri Gut; Daniel E Goldberg; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.

Authors:  Katherine T Andrews; David P Fairlie; Praveen K Madala; John Ray; David M Wyatt; Petrina M Hilton; Lewis A Melville; Lynette Beattie; Donald L Gardiner; Robert C Reid; Martin J Stoermer; Tina Skinner-Adams; Colin Berry; James S McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.

Authors:  Andrew Owen; Omar Janneh; Ruben C Hartkoorn; Becky Chandler; Patrick G Bray; Phillip Martin; Stephen A Ward; C Anthony Hart; Saye H Khoo; David J Back
Journal:  J Pharmacol Exp Ther       Date:  2005-05-27       Impact factor: 4.030

6.  Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin.

Authors:  Donald L Gardiner; Katharine R Trenholme; Tina S Skinner-Adams; Colin M Stack; John P Dalton
Journal:  J Biol Chem       Date:  2005-11-14       Impact factor: 5.157

7.  Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.

Authors:  Sunil Parikh; Jiri Gut; Eva Istvan; Daniel E Goldberg; Diane V Havlir; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 8.  Contribution of the pfmdr1 gene to antimalarial drug-resistance.

Authors:  Manoj T Duraisingh; Alan F Cowman
Journal:  Acta Trop       Date:  2005-06       Impact factor: 3.112

9.  The role of Plasmodium falciparum food vacuole plasmepsins.

Authors:  Jun Liu; Ilya Y Gluzman; Mark E Drew; Daniel E Goldberg
Journal:  J Biol Chem       Date:  2004-10-28       Impact factor: 5.157

10.  Nucleus may be the key site of chloroquine antimalarial action and resistance development.

Authors:  Gao-De Li
Journal:  Med Hypotheses       Date:  2006-03-23       Impact factor: 1.538
View more
  27 in total

1.  HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro.

Authors:  Lokesh C Mishra; Amit Bhattacharya; Manish Sharma; Virendra K Bhasin
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

2.  Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.

Authors:  Zhengxiang He; Li Qin; Lili Chen; Nanzheng Peng; Jianlan You; Xiaoping Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

3.  Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.

Authors:  Christopher L Peatey; Katherine T Andrews; Nina Eickel; Timothy MacDonald; Alice S Butterworth; Katharine R Trenholme; Donald L Gardiner; James S McCarthy; Tina S Skinner-Adams
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

4.  Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.

Authors:  Youjia Li; Li Qin; Nanzheng Peng; Guangjie Liu; Siting Zhao; Zhengxiang He; Xiaoping Chen
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

5.  Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by Plasmodium falciparum Genotype.

Authors:  Megan R Ansbro; Zina Itkin; Lu Chen; Gergely Zahoranszky-Kohalmi; Chanaki Amaratunga; Olivo Miotto; Tyler Peryea; Charlotte V Hobbs; Seila Suon; Juliana M Sá; Arjen M Dondorp; Rob W van der Pluijm; Thomas E Wellems; Anton Simeonov; Richard T Eastman
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-02

6.  Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.

Authors:  Subathdrage D M Sumanadasa; Christopher D Goodman; Andrew J Lucke; Tina Skinner-Adams; Ishani Sahama; Ashraful Haque; Tram Anh Do; Geoffrey I McFadden; David P Fairlie; Katherine T Andrews
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

7.  HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.

Authors:  Kimberly A Porter; Stephen R Cole; Joseph J Eron; Yu Zheng; Michael D Hughes; Shahin Lockman; Charles Poole; Tina S Skinner-Adams; Mina Hosseinipour; Doug Shaffer; Ronald D'Amico; Frederick K Sawe; Abraham Siika; Elizabeth Stringer; Judith S Currier; Tsungai Chipato; Robert Salata; James S McCarthy; Steven R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

8.  HIV treatments have malaria gametocyte killing and transmission blocking activity.

Authors:  Charlotte V Hobbs; Takeshi Q Tanaka; Olga Muratova; Jillian Van Vliet; William Borkowsky; Kim C Williamson; Patrick E Duffy
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

9.  Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.

Authors:  U Lek-Uthai; R Suwanarusk; R Ruengweerayut; T S Skinner-Adams; F Nosten; D L Gardiner; P Boonma; K A Piera; K T Andrews; B Machunter; J S McCarthy; N M Anstey; R N Price; B Russell
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

10.  The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study.

Authors:  Sarah Hochman; Kami Kim
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.